Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 6/20 | 0.32 |
| ▸ | ACHE | P22303 | 6/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19601097 | 0.84 | MEN1 (0.48) | BCHEACHELMNANPC1TP53 | |
| SCHEMBL19601098 | 0.83 | ACHE (0.41) | BCHEACHELMNARAB9ASMN1; SMN2 | |
| SCHEMBL16563233 | 0.80 | KIF11 (0.45) | TSHRBCHEACHELMNAKIF11 | |
| SCHEMBL19601114 | 0.80 | ACHE (0.41) | BCHEACHELMNATP53SMN1; SMN2 | |
| SCHEMBL19601083 | 0.80 | ACHE (0.39) | BCHEACHELMNARAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3136051 | 0.79 | KIF11 (0.48) | TSHRBCHEACHELMNAKIF11 | |
| SCHEMBL19607240 | 0.77 | ACHE (0.44) | BCHEACHENPC1RAB9AALDH1A1 | |
| SCHEMBL19607402 | 0.76 | KIF11 (0.35) | TSHRBCHEACHELMNAKIF11 | |
| SCHEMBL19607338 | 0.75 | ACHE (0.39) | BCHEACHELMNARAB9ASMN1; SMN2 | |
| SCHEMBL19601090 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230126380-A1 | ELECTROCHROMIC DEVICE, LENS UNIT, IMAGING DEVICE, WINDOW MEMBER, AND METHOD OF DRIVING ELECTROCHROMIC ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2023-04-27 | — | — | US | disclosed |
| US-10310350-B2 | Organic compound, electrochromic compound, and electrochromic element, optical filter, lens unit, imaging device, and window component having same | CANON KABUSHIKI KAISHA (JP) | 2019-06-04 | — | — | US | disclosed |
| US-20170329195-A1 | ORGANIC COMPOUND, ELECTROCHROMIC COMPOUND, AND ELECTROCHROMIC ELEMENT, OPTICAL FILTER, LENS UNIT, IMAGING DEVICE, AND WINDOW COMPONENT HAVING SAME | CANON KABUSHIKI KAISHA (JP) | 2017-11-16 | — | — | US | disclosed |
| US-20170329195-A1 | ORGANIC COMPOUND, ELECTROCHROMIC COMPOUND, AND ELECTROCHROMIC ELEMENT, OPTICAL FILTER, LENS UNIT, IMAGING DEVICE, AND WINDOW COMPONENT HAVING SAME | CANON KABUSHIKI KAISHA (JP) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10310350-B2 | Organic compound, electrochromic compound, and electrochromic element, optical filter, lens unit, imaging device, and window component having same | KCNJ2, KCNH3, KCNN2 | TSHR 2840/4885BCHE 2668/4885ACHE 416/4885 |
| US-20170329195-A1 | ORGANIC COMPOUND, ELECTROCHROMIC COMPOUND, AND ELECTROCHROMIC ELEMENT, OPTICAL FILTER, LENS UNIT, IMAGING DEVICE, AND WINDOW COMPONENT HAVING SAME | KCNJ2, KCNH3, KCNN2 | TSHR 2840/4885BCHE 2668/4885ACHE 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.